New pill shows promise in early cancer trial

NCT ID NCT06923761

Recruiting now Disease control Sponsor: Grey Wolf Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests an experimental drug called GRWD5769, taken as a pill, for people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to check safety and find the right dose, and second, to see if the drug shrinks tumors when used alone or with another cancer medicine. About 300 adults will take part, and researchers will monitor side effects and tumor changes over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GRWD5769 (an experimental drug taken by mouth)

What this could lead to

If it works, this could point toward a new treatment option for people with advanced solid cancers that have not responded to other therapies.

What could go wrong

This is an early, first-in-human trial, so the drug may not be safe or effective. Side effects are unknown, and the study is small, so results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hepatocellular carcinoma Liver Neoplasms lung neoplasm neoplasm Squamous Cell Carcinoma of Head and Neck Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANCY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alfred Health
RECRUITING

Melbourne, Australia
Austin Health
RECRUITING

Heidelberg, Australia
Blacktown Hospital
RECRUITING

Blacktown, Australia
Cancer Care Wollongong
RECRUITING

Wollongong, Australia
Centre Eugène Marquis
RECRUITING

Rennes, France
Centre Léon Bérard
RECRUITING

Lyon, France
Christie NHS Foundation Trust
RECRUITING

Manchester, United Kingdom
Clatterbridge Cancer Centre
RECRUITING

Liverpool, United Kingdom
Clinica Universitaria de Navarra Madrid
RECRUITING

Madrid, Spain
Clinica Universitaria de Navarra Pamplona
RECRUITING

Pamplona, Spain
GenesisCare Research
WITHDRAWN

Adelaide, Australia
Hammersmith Hospitals NHS Trust
RECRUITING

London, United Kingdom
Hospital Universitario Vall d'Hebrón (VHIO)
RECRUITING

Barcelona, Spain
Hospital Universitario Virgen de la Victoria
RECRUITING

Málaga, Spain
ICANS - Institut de Cancérologie Strasbourg
RECRUITING

Strasbourg, France
INCLIVA-Hospital Clínico Universitario de Valencia
RECRUITING

Valencia, Spain
IUCT Oncopole - Institut Claudius Regaud
RECRUITING

Toulouse, France
Institut Gustave Roussy
RECRUITING

Villejuif, France
Institut Paoli-Calmettes
RECRUITING

Marseille, France
Institut de Cancérologie de l'Ouest (ICO)
RECRUITING

Saint-Herblain, France
Kinghorn Cancer Centre (KCC)
RECRUITING

Darlinghurst, Australia
Mater Research
RECRUITING

South Brisbane, Australia
Newcastle Upon Tyne Hospital
RECRUITING

Newcastle, United Kingdom
Royal Free Hospital
RECRUITING

London, United Kingdom
START Barcelona - Hospital HM Nou Delfos
RECRUITING

Barcelona, Spain
START Madrid - Centro Integral Oncológico Clara Campal (HM CIOCC)
RECRUITING

Madrid, Spain
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
RECRUITING

Madrid, Spain
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITING

Bedford Park, Australia
Western General Hospital
RECRUITING

Edinburgh, United Kingdom